Delivery Order SPE2DB25D3017-SPE2DB25FVKGN
- Not listed
- The Defense Logistics Agency awarded AmerisourceBergen Drug Corp a delivery order valued at $29,860.78 for Dupixent 300 mg/2 ml syringes on August 15, 2025, with an ultimate completion date of August 18, 2025. This firm fixed-price contract, which is not set-aside, will be performed at the company's corporate office in Conshohocken, Pennsylvania. Dupixent (dupilumab) is a biologic medication used to treat moderate-to-severe atopic dermatitis, asthma, and other inflammatory conditions, making...
- The Defense Logistics Agency awarded a delivery order valued at $45,626.04 to AmerisourceBergen Drug Corp for the supply of Dupixent 300 mg/2 mL syringes on August 18, 2025, with completion scheduled for August 19, 2025. This firm fixed price contract represents a non-competitive delivery order issued under an existing contract vehicle and will be performed at the vendor's Conshohocken, Pennsylvania location. Dupixent is a biologic medication used to treat eczema, asthma, and other...
- The Defense Logistics Agency awarded a $31,152.11 delivery order to AmerisourceBergen Drug Corp on August 4, 2025, for the supply of Dupixent 200 mg/1.14 mL syringes with a completion date of August 5, 2025. This is a firm fixed-price, competitively awarded contract with no set-aside designation. The product will be delivered to AmerisourceBergen's location in Conshohocken, Pennsylvania. This delivery order is issued under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA...
- The Defense Logistics Agency awarded a $14,845.54 delivery order to AmerisourceBergen Drug Corp for Dupixent 300 mg/2 ml syringes on July 23, 2025, with completion scheduled for July 24, 2025. This competitively awarded, firm fixed price contract contains no set-aside designation and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. Dupixent (dupilumab) is a biologic medication primarily used to treat moderate-to-severe atopic dermatitis,...
- The Defense Logistics Agency awarded AmerisourceBergen Drug Corp a delivery order valued at $1,709.46 for Dupixent 300 mg/2 ml syringes on August 1, 2025, with an ultimate completion date of August 4, 2025. This non-set-aside, competitively awarded contract utilizes firm fixed pricing and will be performed at the contractor's facility in Conshohocken, Pennsylvania. Dupixent (dupilumab) is a biologic medication used to treat moderate-to-severe eczema, asthma, and other allergic conditions,...
- The Defense Logistics Agency awarded a $18,005.78 delivery order to AmerisourceBergen Drug Corp for Dupixent 300 mg/2 ml syringes on July 22, 2025, with an ultimate completion date of July 23, 2025. This competitively awarded, non-set-aside contract utilizes firm fixed pricing and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. The delivery order is issued under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop...
- The Defense Logistics Agency awarded a $67,172.41 delivery order to AmerisourceBergen Drug Corp for the supply of Dupixent 300 mg/2 ml syringes. The contract, which is not set-aside and carries a firm fixed price, was awarded on August 4, 2025, with an ultimate completion date of August 5, 2025. AmerisourceBergen will perform the work at its corporate office location in Conshohocken, Pennsylvania. This delivery order is issued under the company's larger Indefinite Delivery Contract (IDC) with...
- The Defense Logistics Agency awarded a delivery order valued at $6,837.84 to AmerisourceBergen Drug Corp for the supply of Dupixent 300 mg/2 mL syringes on July 23, 2025, with completion scheduled for July 24, 2025. This competitively awarded, firm fixed-price delivery order was issued without set-aside designation and will be performed at the contractor's corporate office location in Conshohocken, Pennsylvania. Dupixent (dupilumab) is a biologic immunosuppressant medication commonly used to...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for Dupixent 300 mg/2 ml syringes valued at $2,022.79 on August 4, 2025, with completion scheduled for August 5, 2025. This non-set-aside, competitively awarded contract employs firm fixed-price terms and is performed at AmerisourceBergen's corporate office in Conshohocken, Pennsylvania. Dupixent (dupilumab) is a prescription biologic medication used to treat moderate-to-severe eczema, asthma, and other allergic...
- The Defense Logistics Agency awarded a delivery order valued at $33,470.72 to AmerisourceBergen Drug Corp for the supply of Dupixent 300 mg/2 ml syringes on August 5, 2025, with an ultimate completion date of August 6, 2025. This competitively awarded, firm fixed-price delivery order carries no set-aside designation and will be performed at the vendor's location in Conshohocken, Pennsylvania. Dupixent (dupilumab) is a monoclonal antibody used to treat conditions including atopic dermatitis,...
- SPE2DB25D3017Indefinite Delivery Contract
- SPE2DB25D3017-SPE2DB25FVKGNDelivery Order
The Defense Logistics Agency awarded a delivery order valued at $115,476.79 to AmerisourceBergen Drug Corp for the supply of Dupixent 300 mg/2 mL syringes on August 18, 2025, with an ultimate completion date of August 19, 2025. This firm fixed price delivery order, which carries no set-aside designation, will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. Dupixent is a biologic medication used to treat various inflammatory conditions including eczema, asthma, and chronic rhinosinusitis, making this procurement critical for military and federal healthcare system support. This delivery order is issued under AmerisourceBergen's broader Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, designated SPE2DX, which carries a total potential value of $999,999,999.00 through December 2026. As a major pharmaceutical distributor serving federal medical procurement needs, AmerisourceBergen has demonstrated capability to fulfill diverse pharmaceutical supply requirements across the Defense Health Agency and other government healthcare systems. The company's status as a competitively awarded prime vendor reflects its significant role in supporting the military's pharmaceutical supply chain on a global scale.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $115.5k | 8/18/25 |